Dataset Information

SCI1 co-purifies with the STRIPAK protein PRO11

ABSTRACT: The STRIPAK complex is a conserved multi-protein complex, which is found in animals and in fungi but not in prokaryotes and plants. It is involved in growth and development, regulating signal transduction in cellular pathways, for example hippo and MAPK, and it has a role in human neuronal diseases, cell fusion, and cancer (1, 2). Small coiled-coil (CC) proteins were described in the STRIPAK complex of humans, in the Far complex of S. cerevisiae, in the SIP complex of S. pombe and in the STRIPAK complex of D. melanogaster (dSTRIPAK) (3-8). However, the function of small CC proteins in the STRIPAK complex is poorly investigated. We identified SCI1, a small CC protein belonging to the STRIPAK complex in the filamentous ascomycete S. macrospora. As all other STRIPAK components, SCI1 is required for development, hyphal fusion and vegetative growth.

INSTRUMENT(S): LTQ Orbitrap

ORGANISM(S): Sordaria Macrospora K-hell

SUBMITTER: Oliver Valerius

LAB HEAD: Stefanie Pöggeler

PROVIDER: PXD008959 | Pride | 2018-08-21

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

Items per page:

1 - 5 of 28

Publications

A novel STRIPAK complex component mediates hyphal fusion and fruiting-body development in filamentous fungi.

J Reschka Eva E Nordzieke Steffen S Valerius Oliver O Braus Gerhard H GH Pöggeler Stefanie S

Molecular microbiology 20181021 4

The STRIPAK complex is involved in growth, cell fusion, development and signaling pathways, and thus malfunctions in the human STRIPAK complex often result in severe neuronal diseases and cancer. Despite the high degree of general conservation throughout the complex, several STRIPAK complex-associated small coiled-coil proteins of animals and yeasts are not conserved across species. As there are no data for filamentous ascomycetes, we addressed this through affinity purification with HA-tagged s ...[more]

PMID: 30107058

Similar Datasets

Project description:Adverse outcome pathways (AOP) contain summarizing sequences of key events (KE) relating toxicant exposures to specific adverse outcomes (AO) observed in exposed populations. Quantitative AOPs (qAOP) provide frameworks to assess AO risks based on KE quantification and the modeling of their relationships. This work aimed to develop the quantitative component of AOP 411 <Oxidative stress leading to decreased lung function>. To examine the pertinence of the resulting qAOP-based risk assessment approach, we applied it to predict the medium-term lung function evolution after switching from combustible cigarettes (CC) to heated tobacco products (HTP). We used publicly available data for oxidative stress (in vitro), ciliary beating frequency (in vitro), mucociliary clearance (human), and lung function (human). Following the course of smoking-related lung function decline (Fletcher and Peto, 1977, PMID 871704), we assumed a non-monotonic time evolution where the risk of the AO <decreased lung function> begins to decline after quitting smoking CC or switching to HTP use. Consequently, we designed our qAOP to evaluate the relative reduction (RR) of AO risk for HTP switching compared to the two scenarios of continuing or quitting CC consumption. We developed both data- and physiology-based KE relationship (KER) models. Despite sparse data with respect to dose- and time-response relationships, we successfully connected the measured KEs through in silico KER models. We then used the resulting qAOP to evaluate the exposure effects of switching from CC smoking to HTP use along AOP 411. This approach enabled in silico prediction of the AO RR for which in vivo data were not yet available. In summary, our qAOP provides a multiscale mechanistic approach to evaluate medium-term lung function evolution for the use case of switching from CC smoking to HTP use. The presented approach demonstrates how 21st Century Toxicology principles such as in vitro testing and in silico predictions can be integrated to achieve a meaningful risk assessment approach. It also represents a starting point for integrating additional AOP into an extended AOP network that includes other mechanisms leading to decreased lung function.

			Action	DRS
	ER34.msf	Msf
	ER34.raw	Raw
	ER35.msf	Msf
	ER35.raw	Raw
	ER36.msf	Msf